We are live on ! Find out more
PHS

PFM Health Sciences Portfolio holdings

AUM $1.1B
1-Year Est. Return 57.92%
This Fund
S&P 500
This Quarter Est. Return
+40.41%
1 Year Est. Return
+57.92%
3 Year Est. Return
+183.93%
5 Year Est. Return
+283%
10 Year Est. Return
+2,507.28%
AUM
$1.93B
AUM Growth
+$710M
Cap. Flow
+$347M
Cap. Flow %
17.99%
Top 10 Hldgs %
33.69%
Holding
94
New
31
Increased
15
Reduced
22
Closed
18

Top Buys

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$61.8M
2
LH icon
Labcorp
LH
+$50M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$48.9M
4
AZN icon
AstraZeneca
AZN
+$32.8M
5
HOLX
Hologic
HOLX
+$30.1M

Top Sells

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$38.5M
2
BDX icon
Becton Dickinson
BDX
+$34.7M
3
CI icon
Cigna
CI
+$34.5M
4
ELV icon
Elevance Health
ELV
+$33.1M
5
COR icon
Cencora
COR
+$30M

Sector Composition

Rank Sector Weight
1 Healthcare 66.7%
2 Technology 4.27%
3 Consumer Discretionary 1.32%
4 Industrials 0.62%
5 Financials 0.44%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BIIB icon
76
Biogen
BIIB
$30.9B
– –
-81,013
Closed -$25.6M
CI icon
77
Cigna
CI
$71.9B
– –
-194,690
Closed -$34.5M
CNC icon
78
Centene
CNC
$33.6B
– –
-307,441
Closed -$18.3M
COR icon
79
Cencora
COR
$61.7B
– –
-338,732
Closed -$30M
INSM icon
80
Insmed
INSM
$21.8B
– –
-228,781
Closed -$3.67M
PFE icon
81
Pfizer
PFE
$145B
– –
-1,244,414
Closed -$38.5M
SAGE
82
DELISTED
Sage Therapeutics
SAGE
– –
-436,477
Closed -$12.5M
ZLAB icon
83
Zai Lab
ZLAB
$2.06B
– –
-84,387
Closed -$4.34M
RETA
84
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
– –
-97,864
Closed -$14.1M
ACOR
85
DELISTED
Acorda Therapeutics
ACOR
– –
-12,718
Closed -$1.42M
COUP
86
DELISTED
Coupa Software Incorporated
COUP
– –
-20,909
Closed -$2.92M
XLNX
87
DELISTED
Xilinx Inc
XLNX
– –
-124,677
Closed -$9.72M
XLRN
88
DELISTED
Acceleron Pharma
XLRN
– –
-61,400
Closed -$5.52M
MYOK
89
DELISTED
MyoKardia, Inc. Common Stock
MYOK
– –
-35,592
Closed -$1.67M
1 2 3
4

Similar funds

DAM
Delta Asset Management Memphis, Tennessee $1.1B AUM 14.89% 1-Year Est. Return
MAM
Mark Asset Management New York $1.1B AUM 43.79% 1-Year Est. Return
LCM
Legato Capital Management San Francisco, California $1.1B AUM 61.65% 1-Year Est. Return
DAM
DLD Asset Management New York $1.1B AUM 4.68% 1-Year Est. Return
KCM
Khrom Capital Management Miami Beach, Florida $1.09B AUM 14.82% 1-Year Est. Return
CF
Corebridge Financial Houston, Texas $1.09B AUM 1.85% 1-Year Est. Return
MIA
MMBG Investment Advisors Miami, Florida $1.09B AUM 30.96% 1-Year Est. Return
YL
YCG LLC Austin, Texas $1.1B AUM 4.87% 1-Year Est. Return

PFM Health Sciences's Q2 2020 Portfolio in Review

As of Q2 2020, PFM Health Sciences held 94 positions worth $1.93B, up 58% from $1.22B the previous quarter. Its ten largest holdings account for 34% of the portfolio.

PFM Health Sciences deployed $347M of net new capital in Q2 2020, opening 31 new positions and adding to 15 existing holdings. Its largest new stake was Labcorp: 361,224 shares worth $51.5M.

By sector, the portfolio is most concentrated in Healthcare at 67% of assets, down from 84% a quarter earlier, followed by Technology and Consumer Discretionary.

On the sell side, the largest reduction was Elevance Health, an estimated $33.1M trimmed.

  • PFM Health Sciences's largest Q2 2020 buy was Labcorp: 361,224 shares worth $51.5M.
  • PFM Health Sciences added most to Immunomedics Inc in Q2 2020, an estimated $61.8M increase.
  • PFM Health Sciences's biggest Q2 2020 reduction was Elevance Health, cutting an estimated $33.1M.
  • PFM Health Sciences fully exited Pfizer in Q2 2020, selling an estimated $38.5M.
  • PFM Health Sciences's ten largest holdings make up 34% of its $1.93B portfolio in Q2 2020.
  • PFM Health Sciences opened 31 new positions and closed 18 in Q2 2020.
  • PFM Health Sciences's portfolio value rose 58% quarter-over-quarter to $1.93B.

Based on PFM Health Sciences's 13F filing for Q2 2020, filed 14 Aug 2020.